Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | KAT2B | Q92831 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.39 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL390986 | 0.83 | MAP2K1 (0.58) | MAPK1MAP2K2MAP2K1 | |
| SCHEMBL15826953 | 0.81 | KMT2A (0.40) | KMT2AMEN1TSHRCYP3A4KAT2B | |
| SCHEMBL15826954 | 0.80 | KMT2A (0.42) | KMT2AMEN1KAT2BMAPK1TDP1 | |
| SCHEMBL25944210 | 0.77 | RAPGEF4 (0.46) | KMT2AMEN1MAPK1MAP2K2MAP2K1 | |
| SCHEMBL22583718 | 0.77 | MAPK1 (0.51) | KMT2AMEN1TSHRCYP3A4KAT2B | |
| SCHEMBL22474667 | 0.77 | KMT2A (0.61) | KMT2AMEN1TSHRCYP3A4TDP1 | |
| SCHEMBL247992 | 0.75 | TSHR (0.67) | KMT2AMEN1TSHRCYP3A4KAT2B | |
| SCHEMBL29384695 | 0.75 | TSHR (0.67) | KMT2AMEN1TSHRCYP3A4KAT2B | |
| SCHEMBL19050822 | 0.75 | MAP2K1 (0.43) | KMT2AMEN1CYP3A4MAPK1TDP1 | |
| SCHEMBL11595300 | 0.75 | MAPK1 (0.44) | KMT2AMEN1TSHRCYP3A4KAT2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170183333-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK | ARDEA BIOSCIENCES, INC. (US) | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183333-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK | BRAF, NRAS, MAP3K2 | KMT2A 502/4885MEN1 1666/4885TSHR 2663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.